✳flâneur — a map of the web's best reading
New Genzyme pill will cost patients $310,250 a year - The Boston Globe
web.archive.org · 755 words · saved by 1 readers
Cambridge biotech Genzyme has priced its new pill to treat Gaucher disease at $310,250 a year for the small population of US patients suffering from the rare genetic disorder.
Explore this link on the map →saved by
related reading
- Eliglustat - Wikipediaen.wikipedia.org
- Press Release: Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher diseasesanofi.com
- The Practical Guide to Superbabies — LessWronglesswrong.com
- Medical breakthroughs in 2025 - by Saloni Dattaniscientificdiscovery.dev
- UpToDateuptodate.com
- The 23andMe Deal - Cremieux Recueilcremieux.xyz
- Nature's drug database - The Works in Progress Newsletterworksinprogress.news
- OpenAI | Research & Deploymentopenai.com
- the drug landscapegenome-browser-eight.vercel.app
- Breaking News: Historical Drop of DR-TB Treatment Cost Below $300 After Third Major Cut in 2025 by Stop TB’s Global Drug Facility | Stop TB Partnershipstoptb.org
- NIH study suggests people with rare diseases face significantly higher health care costs | National Institutes of Health (NIH)nih.gov
- Huntington's disease successfully treated for first timebbc.com